glp-1 no bmi requirement agonists and changes in body mass and composition in adults with overweight or obesity with or without type 2 diabetes mellitus: a systematic review and meta-analysis Nearly Four Million Medicare Beneficiaries

Additionally, the drugs have been called anti-obesity medications (AOMs) by some researchers who criticize the drugs for the possibility of severe side effects, the lack of research into long-term use and the possibility of triggering eating disorders in some patients

In preclinical research environments, this compound has been studied for its interaction with both GLP-1 and GIP receptor systems, allowing researchers to evaluate dual incretin signaling pathways within controlled laboratory models

[1] Cell Line:Cultured Sprague-Dawley rat Achilles tendon fibroblasts (passages 2-4) Concentration:0, 0.5, 1, 2 g/mL Incubation Time:24 h Result:Did not alter total FAK, paxillin, or PCNA protein levels

Research is investigating its potential to alleviate symptoms of fatigue and improve sleep quality in patients with this condition

The dose of CNO injected did not affect glycaemia or insulinemia per se in WD mice injected with a control AAV ( Glp1r OBDIO-mCherry WD mice